Literature DB >> 6780019

Management of severely brittle diabetes by continuous subcutaneous and intramuscular insulin infusions: evidence for a defect in subcutaneous insulin absorption.

J C Pickup, P D Home, R W Bilous, H Keen, K G Alberti.   

Abstract

Severely brittle diabetes is defined as a rare subtype of insulin-dependent diabetes with wide, fast, unpredictable, and inexplicable swings in blood glucose concentration, often culminating in ketoacidosis or hypoglycaemic coma. To assess the role of inappropriate type, amount, or timing of insulin treatment and the route of administration as a cause of severe brittleness six patients with continuous subcutaneous insulin infusion, which provides a high degree of optimisation of dosage with exogenous insulin in stable diabetics. The glycaemic control achieved during continuous subcutaneous insulin infusion was compared with that during continuous intramuscular insulin infusion. Six patients with non-brittle diabetes were also treated by continuous subcutaneous insulin infusion. These patients achieved the expected improvement in glycaemic control (mean +/- SD plasma glucose concentration 5.1 +/- 2.3 mmol/l (92 +/- 41 mg/100 ml)), but not the patients with brittle diabetes remained uncontrolled with continuous subcutaneous infusion (13.6 +/- 5.8 mmol/1 (245 +/- 105 mg/100 ml) compared with 10.3 +/- 4.1 mmol/l (186 +/- 74 mg/100 ml) during treatment with optimised conventional subcutaneous injections). During continuous intramuscular infusion, however, glycaemic control in five of the patients with brittle diabetes was significantly improved (7.7 +/- 2.6 mmol/l (139 +/- 47 mg/100 ml). The remaining patient with brittle diabetes, previously safely controlled only with continuous intravenous insulin, did not respond to continuous intramuscular infusion. It is concluded that in five of the six patients with brittle diabetes studied here impaired or irregular absorption of insulin from the subcutaneous site played a more important part in their hyperlability than inappropriate injection strategies. This absorption defect was presumably bypassed by the intramuscular route.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6780019      PMCID: PMC1504135          DOI: 10.1136/bmj.282.6261.347

Source DB:  PubMed          Journal:  Br Med J (Clin Res Ed)        ISSN: 0267-0623


  19 in total

Review 1.  Brittle diabetes.

Authors:  R Tattersall
Journal:  Clin Endocrinol Metab       Date:  1977-07

2.  Aprotinin and insulin resistance.

Authors:  J C Pickup; R W Bilous; H Keen
Journal:  Lancet       Date:  1980-07-12       Impact factor: 79.321

3.  Defective absorption of injected insulin.

Authors: 
Journal:  Lancet       Date:  1978-09-30       Impact factor: 79.321

4.  Continuous subcutaneous insulin infusion in the treatment of diabetes mellitus.

Authors:  J C Pickup; H Keen; G C Viberti; M C White; E M Kohner; J A Parsons; K G Alberti
Journal:  Diabetes Care       Date:  1980 Mar-Apr       Impact factor: 19.112

5.  Insulin resistance caused by massive degradation of subcutaneous insulin.

Authors:  E P Paulsen; J W Courtney; W C Duckworth
Journal:  Diabetes       Date:  1979-07       Impact factor: 9.461

6.  Reduction to normal of plasma glucose in juvenile diabetes by subcutaneous administration of insulin with a portable infusion pump.

Authors:  W V Tamborlane; R S Sherwin; M Genel; P Felig
Journal:  N Engl J Med       Date:  1979-03-15       Impact factor: 91.245

7.  Continuous subcutaneous insulin infusion: an approach to achieving normoglycaemia.

Authors:  J C Pickup; H Keen; J A Parsons; K G Alberti
Journal:  Br Med J       Date:  1978-01-28

8.  Restoration of normal lipid and aminoacid metabolism in diabetic patients treated with a portable insulin-infusion pump.

Authors:  W V Tamborlane; R S Sherwin; M Genel; P Felig
Journal:  Lancet       Date:  1979-06-16       Impact factor: 79.321

9.  Continuous subcutaneous insulin infusion: improved blood-glucose and intermediary-metabolite control in diabetics.

Authors:  J C Pickup; H Keen; J A Parsons; K G Alberti; A S Rowe
Journal:  Lancet       Date:  1979-06-16       Impact factor: 79.321

10.  OBSERVATIONS ON THE ETIOLOGY AND THERAPY OF "BRITTLE" DIABETES.

Authors:  G D MOLNAR
Journal:  Can Med Assoc J       Date:  1964-04-18       Impact factor: 8.262

View more
  21 in total

1.  Drug delivery by program or sensor controlled infusion devices.

Authors:  M Franetzki
Journal:  Pharm Res       Date:  1984-11       Impact factor: 4.200

Review 2.  Perioperative management of endocrine insufficiency after total pancreatectomy for neoplasia.

Authors:  Ajay V Maker; Raashid Sheikh; Vinita Bhagia
Journal:  Langenbecks Arch Surg       Date:  2017-07-21       Impact factor: 3.445

3.  Brittle diabetes.

Authors:  R Tattersall
Journal:  Br Med J (Clin Res Ed)       Date:  1985-08-31

4.  Subcutaneous degradation of insulin.

Authors:  R W Stevenson
Journal:  Diabetologia       Date:  1982-03       Impact factor: 10.122

5.  Long-term continuous intraperitoneal insulin treatment in brittle diabetes.

Authors:  G Pozza; D Spotti; P Micossi; M Cristallo; M Melandri; P M Piatti; L D Monti; A E Pontiroli
Journal:  Br Med J (Clin Res Ed)       Date:  1983-01-22

6.  U100 insulin and insulin absorption.

Authors: 
Journal:  Br Med J (Clin Res Ed)       Date:  1983-04-30

Review 7.  Technology and the diabetic patient.

Authors:  J C Pickup; D Rothwell
Journal:  Med Biol Eng Comput       Date:  1984-09       Impact factor: 2.602

Review 8.  Insulin treatment: a non-stop revolution.

Authors:  J Mirouze
Journal:  Diabetologia       Date:  1983-09       Impact factor: 10.122

9.  Metabolic instability in type I diabetic patients. Studies on insulin absorption, hepatic production of metabolites and glucose counterregulation.

Authors:  P Micossi; M Scavini; F Dosio; L Monti; P M Piatti
Journal:  Acta Diabetol Lat       Date:  1985 Jul-Sep

10.  Unrecognised nocturnal hypoglycaemia masquerading as senile dementia.

Authors:  R Ramasamy
Journal:  Postgrad Med J       Date:  1983-09       Impact factor: 2.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.